Real-World Data on Voclosporin for the Treatment of Lupus Nephritis, Including Use of Concomitant Biologic Therapies: Analysis of the Enlight-LN Registry (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #SA-PO0799; Pres time: Nov 8, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; P | "There were 83 (36.2%) patients on voclosporin who concomitantly received treatment with a biologic including belimumab (28.4%), rituximab (4.8%), anifrolumab (3.9%) and obinutuzumab (1.3%). This is notable given the unique and possibly synergistic effects of these agents on the immune system. Additional analysis of the registry data will provide further clinical and mechanistic insights into the use of these multi-targeted therapeutic approaches."
Clinical • Real-world • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Mohammad Kamgar; Niloofar Nobakht; Laura B. Geraldino-Pardilla; Leanna Marderian Wise; Amber Rosales; Barbara McIntosh; Ronald P. Flauto
|